CYIOS Corp. Appoints John O’Shea as Chief Executive Officer to Lead Next Phase of Growth and Innovation
Rhea-AI Summary
CYIOS Corp (OTC: CYIO) announced on Dec 2, 2025 that John O’Shea has been appointed Chief Executive Officer and Chairman to lead a strategic growth push in medical, technology, and AI-enabled services.
O’Shea brings 30+ years of senior executive and founder experience across finance, SaaS, fintech, and education. Management plans to develop CyioIQ, an AI/SaaS platform to automate operations for Noir Medical Supplies and to commercialize AI capabilities. The company said it will pursue a targeted acquisition and joint venture program in the medical sector, with a stated execution horizon of 24–36 months, while committing to improved governance and regular operational updates.
Positive
- CEO appointment of John O’Shea with 30+ years of experience
- Planned launch of CyioIQ AI/SaaS platform to automate medical-supply operations
- Acquisition strategy targeting medical sector with a 24–36 month execution horizon
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | CEO appointment | Positive | +0.0% | New CEO and chairman to drive AI-enabled medical and SaaS growth strategy. |
| Oct 29 | IR engagement | Positive | +18.4% | Engaged Atlanta Capital Partners to enhance IR and support growth and uplisting. |
| Oct 21 | Leadership transition | Positive | -17.4% | Leadership change, return of preferred shares, and push for audited financials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: one leadership/strategy update aligned positively with price, while another governance-focused transition saw a sharp negative divergence.
Over the last few months, CYIOS has focused on leadership, governance, and capital markets positioning. On Oct 21, 2025, it announced a leadership transition, capital structure simplification, and work toward 2024 and two years of PCAOB-audited statements, which drew a -17.39% reaction. On Oct 29, 2025, the company hired Atlanta Capital Partners for investor relations, supporting plans to reduce legacy debt and scale its CyioIQ AI platform, with shares up 18.42%. Today’s CEO appointment and AI-focused growth plan continues this governance and strategy reset.
Key Terms
ai technical
saas technical
digital-asset lending financial
fintech financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and PALM BEACH, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CYIOS Corp. (OTC: CYIO), a diversified holding company focused on acquiring, building, and scaling high-growth businesses in the medical, technology, and innovation sectors, is pleased to announce the appointment of John O’Shea as its new Chief Executive Officer and Chairman of the Board.
A serial entrepreneur, published author, and seasoned senior executive with more than 30 years of experience across finance, technology, education, and high-growth venture building, O'Shea steps into the role with a bold vision: to transform CYIOS into a modern, AI-enabled powerhouse positioned for long-term expansion through a strategic acquisition strategy within the medical sector and adding shareholder value.
A Proven Leader With Multi-Sector Success
John O'Shea brings an exceptional track record of leadership spanning banking, financial services, insurance, SaaS development, and operational transformation. His diverse background includes:
- Senior Executive roles at Bendigo Bank and Adelaide Bank, where he focused on growth, product innovation, and organizational efficiency.
- Founder & CEO of INCH Corp Pty Ltd, building and scaling technology-enabled solutions across finance and advisory.
- Head of Marketing & Sales at Hannon Insurance & Superannuation, driving national growth strategies.
- Senior Advisor, Sales & Business Development at William M. Mercer, supporting enterprise-level clients across Australia.
- Founder of Helio Lending, an early mover in digital-asset lending and fintech innovation.
- Creator of educational platforms, including nationally adopted sustainability and learning programs in collaboration with RMIT University.
O’Shea’s career is defined by his ability to turn vision into execution, restructure complex organizations, and build aligned teams that accelerate growth.
Driving CYIOS Into the AI Era
In addition to his extensive financial and operational background, O’Shea brings deep experience in applied artificial intelligence, SaaS development, and digital transformation.
Under his leadership, CYIOS has already begun planning CyioIQ, a next-generation AI/SaaS platform designed to automate and optimize operations for Noir Medical Supplies—streamlining procurement, pricing, order flow, customer management, and analytics.
O'Shea intends to leverage AI not only as an internal efficiency driver but also as a commercial product offering, opening a new revenue stream for CYIOS in the rapidly expanding digital health and automation market.
A Transformational Moment for CYIOS Corp.
"This is a transformative moment for CYIOS," said O'Shea. "The Company has a powerful foundation, a growing footprint in the medical supply chain, and significant untapped opportunity across AI, SaaS, and strategic acquisitions. I am energized to lead our talented team as we strengthen operations, expand into new markets, and unlock the full value of our business portfolio."
O'Shea has been instrumental in shaping CYIOS's new strategic direction, focusing on governance improvements, operational transparency, AI-driven efficiencies, and pursuing synergistic acquisitions that support long-term scalability.
Strategic Acquisitions & Joint Ventures in Motion
A significant growth driver for CYIOS will be a strategic acquisition strategy within the medical sector, complemented by targeted joint venture opportunities.
O’Shea has already begun early discussions with multiple acquisition candidates and JV partners, each selected for their ability to strengthen CYIOS’s vertical integration, expand product lines, and enhance distribution capabilities across the United States and the Caribbean.
These acquisitions—combined with the Company's AI roadmap—will form the backbone of CYIOS's growth strategy over the next 24–36 months.
Commitment to Shareholders and Transparent Growth
CYIOS Corp. emphasizes that the new management team is fully aligned with shareholder interests and is committed to professionalized governance, financial clarity, and disciplined execution.
In the coming weeks and months, the Company will issue several operational and strategic updates as part of its commitment to clear, consistent, and transparent communication throughout this next phase of growth.
About CYIOS Corp.
CYIOS Corp. is a diversified holding company focused on acquiring and operating high-growth businesses with an emphasis on medical supplies, AI/SaaS development, and strategic innovation. Through its subsidiary, Noir Medical Supplies, the Company provides high-quality products to healthcare providers across the United States and the Caribbean. CYIOS is actively expanding its portfolio through technology innovation, operational excellence, and data-driven growth strategies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of applicable securities legislation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions, opinions and estimates of management and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of regulatory agencies and regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise, except as required by applicable law.
Media & Investor Relations Contact
David Kugelman
Atlanta Capital Partners, LLC
(866) 692-6847 (U.S. & Canada Toll-Free)
(404) 281-8556 (Mobile / WhatsApp)
dk@atlcp.com
